New Pathways Ketamine Centers Open Bay Area Clinics for Treatment-Resistant Mood Disorders, Invite Clinicians to November 8 Grand Opening
Centers are first in Bay Area to be managed by psychiatrists to offer this new treatment
SAN FRANCISCO, Nov. 1, 2017 /PRNewswire/ -- New Pathways Ketamine Centers announce the opening of their new Bay Area clinics (San Francisco and San Mateo) that will offer Ketamine therapy to patients suffering from treatment-resistant mood disorders. "Our team is excited to bring this specialized therapy to patients suffering from depression and other psychiatric disorders," says Dr. Roberto Estrada, New Pathways Ketamine Centers' Medical Director, a nationally recognized expert on neuromodulation and depression therapies.
Earlier this year, the American Psychiatric Association released a consensus statement acknowledging that the drug could be a breakthrough treatment for severe depression. The statement authors write that seven studies--all placebo-controlled, double-blind, and randomized--provide evidence that ketamine therapy is a "rapid and robust, albeit transient" response to severe clinical depression. The treatment is effective within hours, while conventional antidepressants generally take weeks to work. Ketamine has not been approved for treating depression, but has been used "off-label" by psychiatrists such as Dr. Estrada.
"If you're faced with a depressed patient at risk of suicide and they have failed standard antidepressant therapies, you should consider Ketamine therapy a viable treatment option," he added.
New Pathways Ketamine Centers, https://newpathways.co/, are specialty clinics staffed with psychiatrists, nurses and psychotherapists who partner with mental health providers in the community to help patients that have few remaining options for mental health treatment. Although anesthesiologists have been offering ketamine therapy all over the country for the past few years, New Pathways will provide a more comprehensive spectrum of ketamine services, including ketamine-infusion therapy, ketamine-assisted psychotherapy (KAP) and group therapy services. By integrating careful screening and evaluation, psychotherapeutic services, and care coordination with patients' providers, New Pathways hope to set the new gold standard for this psychiatric treatment.
New Pathways is inviting clinicians to their Grand Opening event on November 8, 2017 to learn more about this exciting new therapy and tour their facilities.
New Pathways Board Certified Clinicians
Roberto Estrada, M.D., Medical Director: A nationally-recognized clinical expert in the field of Interventional Psychiatry and Neuromodulation, Dr. Estrada has over 15 years of experience using the latest in cutting-edge technology to treat patients with mood and anxiety disorders. He has been using Transcranial Magnetic Stimulation (TMS), Electroconvulsive Therapy (ECT), Vagus Nerve Stimulation (VNS) and now Ketamine Infusion Therapy (KIT) to safely and effectively treat thousands of patients suffering with psychiatric conditions. Dr. Estrada is a Diplomate of the American Board of Psychiatry and Neurology and is a Fellow of the American Psychiatric Association. He formed Lenox Hill TMS Psychiatric Associates in 2009, and has served as Medical Director for the San Francisco office since 2011. Dr. Estrada completed Visiting Fellowships in ECT and TMS at Columbia University Medical Center and has also received formal clinical training in VNS. He recently completed training in Ketamine Therapy at the 2017 Psychedelic Sciences Conference and Kaiser Permanente's Ketamine Conference.
About Ketamine Therapy
Ketamine is a dissociative anesthetic approved by the FDA in 1970 that in addition to its promise as an antidepressant medication, has also been used effectively in pain management. It has been a popular party drug for decades due to its ability to put users in a blissful mood; however, its newest application, discovered serendipitously in the late 1990s, opened the door for ketamine's potential as a novel antidepressant. NIMH research studies done in 2006 showed that nearly 70% of people with treatment-resistant depression responded to ketamine. To date, more than 75 studies have been done that demonstrate that ketamine is a safe and effective treatment for depression.
Media Contact
Rick Roose
RCI Partners
415.202.4445
[email protected]
References
Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB, for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry.2017;74(4):399-405.
Zarate,C.A., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A…….Manji, H.K. et al. A randomized trial of N-methyl-D-aspartate antagonist in treatment-resistent depression. Archives of General Psychiatry, 2006; 63,856-864.
SOURCE New Pathways Ketamine Centers
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article